AstraZeneca
AZN
About: A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Employees: 94,300
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
130% more call options, than puts
Call options by funds: $596M | Put options by funds: $259M
6% more repeat investments, than reductions
Existing positions increased: 457 | Existing positions reduced: 430
8% less first-time investments, than exits
New positions opened: 99 | Existing positions closed: 108
3% less funds holding
Funds holding: 1,234 [Q1] → 1,203 (-31) [Q2]
8% less capital invested
Capital invested by funds: $37.6B [Q1] → $34.6B (-$2.95B) [Q2]
16.6% less ownership
Funds ownership: 32.58% [Q1] → 15.98% (-16.6%) [Q2]
48% less funds holding in top 10
Funds holding in top 10: 21 [Q1] → 11 (-10) [Q2]
Financial journalist opinion
Based on 16 articles about AZN published over the past 30 days
